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Background: Epidemiological observations regarding certain population-wide parameters (e.g., disease-prevalence,
recurrence-risk in relatives, gender predilections, and the distribution of common genetic-variants) place important
constraints on the possibilities for the genetic-basis underlying susceptibility to multiple sclerosis (MS).
Methods: Using very broad range-estimates for the different population-wide epidemiological parameters, a
mathematical model can help elucidate the nature and the magnitude of these constraints.
Results: For MS no more than 8.5 % of the population can possibly be in the “genetically-susceptible” subset
(defined as having a life-time MS-probability at least as high as the overall population average). Indeed, the
expected MS-probability for this subset is more than 12 times that for every other person of the population who
is not in this subset. Moreover, provided that those genetically susceptible persons (genotypes), who carry the
well-established MS susceptibility allele (DRB1*1501), are equally or more likely to get MS than those susceptible
persons, who don’t carry this allele, then at least 84 % of MS-cases must come from this “genetically susceptible”
subset. Finally, because men, compared to women, are at least as likely (and possibly more likely) to be susceptible,
it can be demonstrated that women are more responsive to the environmental factors that are involved in
MS-pathogenesis (whatever these are) and, thus, susceptible women are more likely actually to develop MS
than susceptible men. Finally, in contrast to genetic susceptibility, more than 70 % of men (and likely also
women) must have an environmental experience (including all of the necessary factors), which is sufficient
to produce MS in a susceptible individual.
Conclusions: As a result, because of these constraints, it is possible to distinguish two classes of persons,
indicating either that MS can be caused by two fundamentally different pathophysiological mechanisms or
that the large majority of the population is at no risk of the developing this disease regardless of their
environmental experience. Moreover, although environmental-factors would play a critical role in both
mechanisms (if both exist), there is no reason to expect that these factors are the same (or even similar)
between the two.
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Complex genetic disorders are those that are caused by
the interaction of multiple genetic and environmental
factors [1]. Many human diseases are examples of such
disorders, including multiple sclerosis (MS) – a common
neurological condition, in which recurrent immune-
mediated injuries occur to the central nervous system
[2, 3]. Epidemiological evidence has implicated the in-
volvement of multiple environmental factors, including
vitamin D deficiency and Epstein-Barr viral infections – see
[3] for a review. Nevertheless, it is on the genetic side that
most of the recent progress has come. The associations of
MS with the human leukocyte antigens (HLA) on the short
arm of chromosome 6 have been known for decades [2–9].
More recently, from several genome-wide association stud-
ies (GWAS) of single-nucleotide polymorphisms (SNPs) in
MS, disease-associations have been identified in more than
150 different non-HLA locations scattered throughout the
genome [4–7]. However, the translation of these associa-
tions into a clinically useful assessment of an individual’s
disease-risk has been limited. This is due to the fact that a
large proportion of the heritability for many complex dis-
eases, including MS, remains unexplained. Indeed, in MS
the 110 genes so far identified (in addition to the HLA as-
sociations) only account for only 28 % of the known hered-
ity [4, 10]. Although a good deal of effort is currently being
made to narrow this so-called “heritability gap”, it is unclear
how likely these efforts are to succeed.
Much will depend upon the underlying basis of genetic
susceptibility. For example, suppose that the individuals
in a population exist on a continuum of susceptibility
(i.e., anyone can develop the illness under the proper cir-
cumstances and a person’s individual genetic make-up
only serves to make this outcome more or less likely to
occur). In this case, although individuals at especially
high-risk could, perhaps, be identified, the development
of a sensitive and specific genetic test for susceptibility,
which could be applied to the population as a whole, will
likely not be possible. By contrast, if only a small segment
of the population is genetically susceptible and only these
susceptible individuals can develop disease, then the task
of developing such a test, should, in theory, be much more
likely to succeed.
The epidemiological observations regarding the various
population-wide parameters such as the disease prevalence,
the recurrence risk in relatives, gender predilections, and
the distribution of common genetic variants (observations
which have been made for years in many different parts of
the world) place important constraints on the possibilities
for the underlying genetic basis of susceptibility. Although
applicable to any complex genetic disease, for illustrative
purposes, this paper considers the nature and magnitude of
these constraints as they apply to the study of MS.
Model overview and implications
Because much of this model development is technical,
an overview of the basic ideas behind the model (and their
implications) is here provided for purposes of clarity.
Thus, in this model, directly-measurable epidemiological
data are used to estimate the likelihood that an individual
from the general population is “genetically-susceptible” to
getting MS. This probability is defined as P(G). The defin-
ition used for this parameter is provided both below and
in Table 1. In order to estimate the value of this parameter,
we define certain other quantities such as the conditional
probability that a “genetically-susceptible” individual will
get MS {P(MS|G)} and the probability that an individual
Table 1 Definitions for estimating the probability of genetic
susceptibility – P(G)
Assume a population (P) of (n) individuals: (i = 1,2,…,n)
P(MS) = The life-time probability of developing
multiple sclerosis (MS) in the population
(Gi) = Genotype of the (i
th) individual in the
population
P(MS│Gi) = zi = Expected life-time probability of MS in
the (ith) individual (genotype)
(G−) = The subset of “non-susceptible” individuals
for whom: P(MS│Gi) = 0
(Gmin) = The subset of “minimally susceptible”
individuals for whom: 0 < P(MS│Gi) < P(MS)
(G) = The subset of “genetically susceptible”
individuals for whom: P(MS│Gi) ≥ P(MS)
(GT–) = the combined subset: (Gmin) ∪ (G–)
(GT) = the combined subset: (Gmin) ∪ (G)
Z, X, Y, W,V = sets of: {zi}; in the entire population (Z); in
the (G) subset (X); in the (G−) subset (Y),




= Expected life-time probability of MS for
individuals in the subsets (G−), (Gmin), or (G).
By definition: P(MS│G) > P(MS│Gmin) >
P(MS│G−) = 0
p, q = p = P(G); q = P(G│MS) = P(G│IGMS)
x, x’, xi = x = P(MS│G); x’ = P(MS│G, IGMS);
xi= P(MS│Gi) given ziε X
y, y’ = y = P(MS│Gmin); y’ = P(MS│Gmin, IGMS)
r = The largest value of P(MS│Gi) in the
population
P(MS│MZMS) = The conditional life-time probability of an
individual developing MS, given that their
monozygotic (MZ)-twin either has or will
develop MS. This is equal to the proband-wise
concordance rate for MZ twins.
P(MS│DZMS),P(MS│SMS) = The equivalent definition as for P(MS│MZMS)
except for the individual having either a
dizygotic (DZ) twin or sibling (S) with MS
P(MS│IGMS) = b = P(MS│MZMS) adjusted for the impact
of an identical genotype (IG) sharing
the same childhood and intrauterine
micro-environments
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with MS is also “genetically-susceptible” {P(MS, G)}. By
the rules of conditional probability we know that:
P Gð Þ ¼ P MS;Gð Þ=P MSjGð Þ
Therefore, in order to estimate P(G), we just need to
know (approximately) what these other two probabilities
are. Fortunately, these other probabilities can be esti-
mated from directly-observed epidemiological data. For
example, it must be the case that P(MS, G) is less than
the probability of MS in the population P(MS) and this
probability, in turn, can be approximated by the mea-
sured prevalence of MS in the population. Also, we will
define the term P(MS|MZMS) as the probability that a
monozygotic (MZ) twin will get MS given that their co-
twin already has (or will develop) MS. This also is a
measureable epidemiological parameter – the proband-
wise (or case-wise) MZ-twin concordance rate for MS
[10]. Moreover, because, this observed rate must be less
than the concordance rate in “genetically-susceptible”
MZ-twins, the observed rate can be used to approximate
the term P(MS|G). Thus, using these two approximations
for the populations of North America and northern Europe
(where these two measured parameters are reasonably well-
established), our estimate for P(G) becomes:
P Gð Þ≈P MSð Þ=P MSjMZMSð Þ≈ 0:001ð Þ= 0:25ð Þ ¼ 0:004
Consequently, this simple “back of the envelope” calcula-
tion suggests that the occurrence of “genetic-susceptibility”
in the population must be extremely rare (~0.4 %). The
present manuscript refines this calculation, providing an es-
timate for the maximum possible value that this probability
(G) can take, given the uncertainties in the estimates for
these two measurable parameters and given the possible re-
lationships that these measureable parameters have to the
actual parameters of interest {i.e., P(MS, G) and P(MS|G)}.
In addition, this markedly asymmetric division of individ-
uals into those who are “genetically-susceptible” and those
who are not has important implications for the nature of
genetic susceptibility to MS. Thus, in contrast to a log-
normal model (in which the odds of MS are increased by
each independent genetic risk factor that a person pos-
sesses), the epidemiological data strongly suggests that most
(possibly all) individuals with MS come from the “genetic-
ally-susceptible” group and that the population is markedly
bimodal with respect to the likelihood (risk) that individual
members of the population will develop MS.
Moreover, there seem to be differences in the nature
of the pathogenesis of MS between men and women.
Thus, genetic risk factors are critical to each. However,
because women comprise almost three quarters of the
MS population, it is perhaps surprising that men are, if
anything, more likely than women to be “genetically-sus-
ceptible” to getting MS. Therefore, because of this fact,
the final gender distribution must be related to environ-
mental factors (either from differences in exposure between
men and women or from differences in the response by
women to a given exposure). The environment is known to
play a critical role in MS-pathogenesis and at least three
separate environmental factors (events) are implicated.
Each of these events occurs in the large majority of individ-
uals within the population (i.e., they are population-wide
environmental events). One event occurs near birth (either
in utero or in the immediate post-natal period), another oc-
curs during adolescence, and a third (and possibly more)
occurs thereafter. Based on the observed epidemiological
data, it can be shown that the basis for the final gender dis-
tribution in MS, and for the increasing proportion of
women in contemporary MS cohorts, is that susceptible
women are much more likely to develop MS than suscep-
tible men under similar environmental conditions.
The remainder of this manuscript (together with the
Additional file 1) is devoted to developing these ideas in
a more rigorous manner.
Methods
Model definitions for determining genetic susceptibility
in MS
1. The definitions used for establishing an upper limit
for the probability of being genetically susceptible
to MS in the population are listed in Table 1.
Consider a population (P0) of (n) individuals (i = 1,2,…,n),
each with their own unique genotype (Gi). Let the term
P(MS) be defined as the expected life-time probability
that a member of the population will develop MS. This
probability is related to a directly-observable popula-
tion parameter – the disease prevalence. Let the ex-
pected life-time probability of getting MS for a specific
individual (i.e., for their unique genotype) be defined as
the conditional probability P(MS|Gi). Let (Z) be the set
of all these individual probability values within the
population. Thus:
Zð Þ ¼ zif g;
where:
∀Gi∈ P0ð Þ : zi ¼ P MSjGið Þ
Further, let the population be partitioned into three
mutually exclusive subsets of individuals based on their
individual expected life-time probability values. These
three subsets (G), (Gmin), and (G-) are defined in the fol-
lowing manner:
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Gð Þ ¼ Gi∈ P0ð ÞjP MSjGið Þ≥P MSð Þf g; P MSjGð Þ ¼ x
Gminð Þ ¼ Gi∈ P0ð ÞjP MSð Þ > P MSjGið Þ > 0f g; P MSjGminð Þ ¼ y
and:
G−ð Þ ¼ Gi∈ P0ð ÞjP MSjGið Þ ¼ 0f g; P MSjG−ð Þ ¼ 0
By these definitions:
x≥P MSð Þ > y > 0
and:
PðGÞ þ PðGminÞ þ PðG−Þ ¼ 1
The subset (G-), members of which have no chance of
getting MS, will be referred to as “non-susceptible”; the
subset (G min), members of which have a very small
chance of getting MS. will be referred to as “minimally-
susceptible”; and the subset (G) will be referred to as
“genetically-susceptible”. Let the sets (X) and (Y) be the
sets of the individual life-time probability values for




∀Gi∈ Gð Þ : xi ¼ P MSjGið Þ
and:
ðY Þ ¼ fyig;
where:
∀Gi∈ Gminð Þ : yi ¼ P MSjGið Þ
Let the combined subset of all genotypes, which are
not in the “genetically-susceptible” subset, be defined as:
ðGT−Þ ¼ ðGminÞ ∪ ðG−Þ
Let the set (V) be the set of the individual life-time
probability values for members of the (GT-) subset.
Thus:
ðV Þ ¼ fvig;
where:
∀Gi∈ GT−ð Þ : vi ¼ P MSjGið Þ
And finally, let the combined subset of all genotypes,
which have a non-zero probability of developing MS (GT),
be defined as:
ðGT Þ ¼ ðGÞ ∪ ðGminÞ
Let the set (W) be the set of the individual life-time
probability values for members of the (GT) subset. Thus:
ðW Þ ¼ fwig;
where:
∀Gi∈ GTð Þ : wi ¼ P MSjGið Þ
Whether defining genetic susceptibility in this manner
or creating these different categories has any utility is
not known. Therefore, the value (if any) of these con-
structs needs to be established. Nevertheless, any popu-
lation can be partitioned in this manner and such a
division makes no assumptions about the underlying dis-
tribution of the individual expected life-time probability
values within the population. For example, if everyone
has the exact same expected life-time probability, P(MS),
then everyone will belong to the subset (G) and the sub-
sets (G min) and (G-) will be empty. If everyone has a
non-zero expected life-time probability of MS, then the
subset (G-) will be empty. If the distribution of individ-
ual expected life-time probability values {wi} within the
(GT) subset is normal and centered at P(MS), then the
two subsets (G) and (G min) will be symmetrical to each
other, P(G) = P(G min), and each subset will have the
half-normal distribution. If the distribution of individual
expected life-time probability values is something else,
then individuals will be assigned to the three subsets ac-
cordingly. For MS, the subset (G) cannot be empty; nei-
ther can it encompass the entire population [2–9].
Results
Estimating the probability of genetic susceptibility – P(G)
2. Therefore, from the definitions provided in (1)
above, the proportion (p) of “genetically susceptible”
individuals in the population (P0) is:
p ¼ P GjP0ð Þ ¼ P Gð Þ > 0
1−p−P G−ð Þ ¼ P Gminð Þ≥0
1−p ¼ P GT−ð Þ > 0
so that:
PðMSÞ ¼ PðGÞxþ PðGminÞy ¼ pxþ f1−p−PðG−Þgy
And also the proportion (q) of “genetically susceptible”
individuals in the subset (MS) is:
q ¼ P GjMSð Þ > 0
and:
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1−qð Þ ¼ P GminjMSð Þ≥0
As previously, we will let the term P(MS|MZMS) be de-
fined as the conditional life-time probability that an
MZ-twin will develop MS, given that his or her co-twin
either already has, or will develop, MS. This probability is
related to a directly-observable population parameter – the
proband-wise (or case-wise) concordance rate for MZ-
twins [10]. Let the purely hypothetical term, P(MS|IGMS),
be introduced to represent the MZ-concordance rate,
which has had the impact of the environment (shared by
the twins) removed. Thus, this term envisions what the
expected concordance rate would be if the MZ-twins,
with their identical genotypes (IG), were to be separated at
conception and to grow up independently in different en-
vironments (both intrauterine and childhood).
Let the term (b) be defined such that:
b ¼ P MSjIGMSð Þ
Because MZ-twins are genetically identical, and because
MZ-twining is thought to be non-genetic, therefore, it is
assumed (see Additional file 1) that:
q ¼ P GjMSð Þ ¼ P GjMZMSð Þ ¼ P GjIGMSð Þ
Let the two quantities (x ') and (y ') be defined such
that:
x0 ¼ P MSjG; IGMSð Þ
and:
y0 ¼ P MSjGmin; IGMSð Þ
so that:
b ¼ qx0 þ 1−qð Þy0
3. From the Additional file 1:
x0 ≥ x ≥ P MSð Þ > y0 ≥ y > 0
Moreover, because (0 < q ≤ 1), the final equation in (2)
above can easily be rearranged to yield:
0 < q ¼ b−y0ð Þ= x0−y0ð Þ≤1
and, therefore:
x0 ≥ b
4. Let the maximum probability of MS (r) within the
set (X) be defined such that:
∀xi; xj∈ðXÞ : xj ¼ r; if it is true that : ∀Gi∈ðGÞ
: xi ≤ xj
By definition, (r) is also the maximum probability
within the set (Z). Moreover, because there must be at
least one person in (X), for whom: xi ≥ b
therefore, it must also be the case that: r ≥ b
5. From the Additional file 1:
x0 ¼ xþ σ2X=x
or:
x2−x0xþ σ2X ¼ 0




and because, by definition:
x > 0






From (3) above, under any circumstance, the following
limits must apply:









This theoretical limit for (σX
2 ) is only slightly greater
than the maximum possible variance for the set (X),
which occurs for a bimodal population [11], in which:
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Pfxi ¼ bg ¼ 0:5;
and:




E Xð Þ ¼ x ¼ bþ P MSð Þf g=2
and:
σ2X ¼ Eðxi−xÞ2 ¼ fr−PðMSÞg2=4 ¼ fb−PðMSÞg2=4
However, these circumstances describe a bimodal popu-
lation. Therefore, if these circumstances pertain, the case
for a bimodal distribution is already made. Consequently,
for any unimodal distribution, (σX
2) must be lower than this
upper-bound and (x) must be greater than this lower-
bound.
6. For example, the uniform distribution is an example
of unimodal distribution, which is evenly spread out
[11]. The uniform distribution is defined such that:
∀xi; xj∈ðXÞ : PðxiÞ ¼ PðxjÞ
where:
σ2X ¼ r−P MSð Þf g2=12
and:
x ¼ r þ P MSð Þf g=2
In this circumstance, from this and from the Add-
itional file 1:
σ2X ¼ x x0−xð Þ ¼ r−P MSð Þf g2=12
which, when (x ' = b), can be rewritten to become:
r þ P MSð Þf gb=2− r þ P MSð Þf g2=4 ¼ r−P MSð Þf g2=12
This last expression is a quadratic in (r), which other-
wise includes only the population parameters {b and
P(MS)} and, thus, (r) in this circumstance can be esti-
mated based on direct epidemiological observations.
7. For a population with a similar age-structure to the
US, the quantity P(MS) will be between one and
two times the population prevalence [2]. The preva-
lence of MS can be very broadly estimated to be
50–250/100,000 in northern populations [2, 3, 12–15],
which yields the range-estimate for P(MS) of:
0:0005≤P MSð Þ≤0:005
To estimate the quantity {b = P (MS|IGMS)} requires
an understanding of the impact that the shared child-
hood and intrauterine micro-environments have on the
likelihood that MS will develop. From multiple observa-
tions, the shared childhood micro-environment seems to
make little difference [15–22]. The shared intrauterine
(IU) micro-environment, by contrast, may be important
[13, 14, 23–29]. Thus, the Canadian data [23] regarding
the recurrence risk for dizygotic (DZ) twins and siblings
(S) suggests that this IU effect may be as large as:
P MSjDZMSð Þ=P MSjSMSð Þ ¼ 0:054=0:029 ¼ 1:86
A similar disparity has been noted in a review of the
available epidemiological data [14]. Nevertheless, in a re-
cent population-based study from Sweden, DZ-twins and
siblings seemed to have the same risk [13, 14].
Assuming the truth lies between these two extremes
then, using a very broad range-estimate for the proband-
wise concordance rates for MZ twins {i.e., P(MS|MZMS)}
in northern populations of between 0.15 and 0.40, inclu-
sive [2, 3, 14, 23–29] yields the range-estimate for (b) of:
0:15=1:86 ¼ 0:081≤ b ¼ P MSjIGMSð Þf g≤0:4
8. Substituting: {b = 0.081 ; and : P(MS) = 0.005} into
the Equations from (6) above, yields the minimum
possible estimate for (x) of:
x ≥ b=2 ≥ 0:081=2 ¼ 0:0405
Because:
P Gð Þ ¼ P MS;Gð Þ=x ≤ 2P MS;Gð Þ=b ≤ 2P MSð Þ=b
therefore:
P Gð Þ ≤ 2P MSð Þ=b ≤ 0:01=0:081 ¼ 0:123
Consequently, under any circumstance, the maximum
possible percentage of the population (P0) that members
of the (G) subset could comprise is 12.3 %.
A lower bound for P(G) can also be established by not-
ing that:
x0 ¼ P MS;GjIGMSð Þ=P GjIGMSð Þ
¼ P MS;GjIGMSð Þ=P GjMSð Þ
Because:
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P Gð Þ ¼ P MS;Gð Þ=x≥P MS;Gð Þ=x0≥ P GjMSð Þf g2 P MSð Þ=bf Þ
And, using the definition of (g) from (Additional file 1:
Table S1) as:
g ¼ P GjMSð Þ
the maximum possible range for P(G) can be expressed as:
g2
 
P MSð Þ=bf g≤P Gð Þ≤ 2ð Þ P MSð Þ=bf g
9. Nevertheless, as noted in (5) above, this particular
upper-bound is that for a bimodal population.
Substituting these same values into the Equations
from (6) above for the uniform distribution {at:
(x ' = b)} yields the minimum (x) and the maximum
variance of (X) for this situation of:
r ¼ 0:121; x ¼ 0:063; σ2X ¼ 0:0011;
and:
σX ¼ 0:034
Notably, however, the largest possible variance for any
unimodal population [11], has been shown to be:
σ2X ¼ x x0−xð Þ ¼ r−P MSð Þf g2=9
Therefore, using the same estimates for {b and P(MS)}
as above, yields
r ¼ 0:113; x ¼ 0:059; σ2X ¼ 0:0013;
and:
σX ¼ 0:036
From (5) above, as either (b) increases or as (x ') in-
creases relative to (b), both the minimum (x) and the
maximum variance of (X) increase.
Despite this slightly larger upper-bound for the variance
of any unimodal distribution compared to the uniform
distribution, several conditions (e.g., the distribution is
symmetrical, the median is equal to x, or the mode is
equal to x) are sufficient to make the maximum variance
be that of the uniform distribution [11]. Nevertheless, the
larger estimate for (σX
2) − i.e., that for any unimodal distri-
bution − and the smaller estimate for the minimum (x)
will be used in the remainder of the calculations.
10. Finally, because the probability of the part cannot
exceed the probability of the whole, it follows that:
P MSð Þ=P Gð Þ≥P MS;Gð Þ=P Gð Þ ¼ P MSjGð Þ ¼ x
Using the result from (9) above that (x ≥ 0.059),
therefore:
P MSð Þ=P Gð Þ ≥ x ≥ 0:059
With simple rearrangement, this condition means that
the maximum possible estimate for the upper-bound of
P(G), given any unimodal distribution of the set (X), is:
P Gð Þ ≤ P MSð Þ=x ≤ 0:005=0:059 ¼ 0:085
11. Recall that the subset of all genotypes that have a
non-zero probability of developing MS was defined as:
ðGT Þ ¼ ðGÞ ∪ ðGminÞ
It is noteworthy, however, that the difference in the ex-
pected life-time probability of MS between these two
subsets of (GT) is substantial.
Thus, because:
P MSjGT−ð Þ≤ y ¼ P MSjGminð Þf g < P MSð Þ≤0:005
and because:
x ¼ P MSjGð Þ ≤ 0:059
Therefore:
x=y ¼ P MSjGð Þ=P MSjGminð Þ > P MSjGð Þ=P MSð Þ
≥ 0:059=0:005 ¼ 12
so that:
x ¼ P MSjGð Þ > 12  P MSð Þ > 12  P MSjGminð Þ
≥ 12  P MSjGT−ð Þ
In fact, by the definition of the (G min) and (G-) sub-
sets, the expected probability of MS in the set (X) is also
more than 12 times the likelihood of MS developing for
every other individual member of the population who is
not in the (G) subset.
Contrast this with the very small difference in subset
means permitted for any symmetric distribution centered
on P(MS). Thus, by the definition of symmetry:
x−P MSð Þ ¼ P MSð Þ−y
Because, by definition:
0 < y < P MSð Þ
Therefore, in this situation:
Goodin BMC Neurology  (2016) 16:56 Page 7 of 12
0 < y < P MSð Þ≤x < 2P MSð Þ
12. From (10) above, the fact that:
P MSjGð Þ ¼ x ≥ 0:059
and:
P Gð Þ≤0:085
and, the definition that:
0 < P MSjGminð Þ ¼ y < P MSð Þ
together with the extreme separation of the subset
mean {P(MS|G)} from the means of the subsets
{P(MS|G min), P(MS|GT−), and P(MS)}, constrain, in
important ways, the possibilities for the distribution of
(Z), which is the set of individual life-time MS prob-
abilities in the population.
For example, the observation that no more than 8.5 %
of the population can possibly be members of a unimodal
subset (G) indicates that (Z) can’t have a symmetric dis-
tribution centered on P(MS). This is because, in such a
circumstance:
∀zi∈ðZÞ : Pðzi∈XÞ ¼ PðGÞ ¼ PðGT−Þ ¼ Pðzi∈V Þ
whereas, in fact:
PðGÞ≤0:085<<0:915≤PðGT−Þ
Indeed, this disparity is so large that it precludes even
a roughly symmetric distribution for (Z), which is cen-
tered on P(MS). Moreover, the extreme separation of
both the subset means {P(MS|GT-) and P(MS|G)}, as well
as the means for the set (G) and the (P0) population {i.e.,
P(MS|G) and P(MS)}, together with the very restricted
range for the MS probabilities {vi} in the set (V) − i.e.,
for individuals in the (GT-) subset − indicates that the
distribution of MS probabilities for the whole population
(Z) must be, at least, bimodal [30]. This is illustrated in
Fig. 1a for the circumstances in which {P(W) ≈ P(Z) = 1}.
The means and variances for the distribution used in
this illustration are based on considerations developed in
(9) above and, for illustrative purposes only, the two dis-
tributions of the bimodal population have been each
represented as normal. Moreover, this distribution could
also be trimodal − i.e., the set (V) could itself be bimodal −
if the both of its subsets {(G min) and (G-)} are non-empty
(e.g., Fig. 1b).
Nevertheless, there are other (unimodal) distributions,
which can also be markedly asymmetric. The question,
therefore, naturally arises as to how confident we are
that the distribution of the odds of MS in the (P0)
population can be distinguished from these unimodal
alternatives. As noted above, the extreme separation of the
sub-set means suggests that the distribution is bimodal
[30]. Nevertheless, the possibility that the distribution con-
forms to a log-normal model needs to be considered care-
fully. In the first place, the log-normal distribution is both
unimodal and asymmetric and, moreover, this asymmetry
can be of any specified degree. In the second place, the
log-normal model has considerable theoretical appeal,
particularly in the setting of a complex disease such as
MS, which is associated with multiple genetic risk fac-
tors [6, 7]. Thus, if these multiple risk factors are inde-
pendent of each other (and there is little doubt that
they are sorted independently), then (by the central
limit theorem) the resulting probability distribution for
the odds of MS will follow a log-normal probability
density function [31]. And, indeed, Clayton and colleagues
recently concluded, based on experimental evidence, that
a log-normal model was appropriate for another complex
genetic disease, which is comparable epidemiologically to
MS – type I diabetes [31].
Similarly, in MS, a log-normal distribution of the odds
could account either for the minimum asymmetry of
91.5 % in (Gmin) and 8.5 % in (G), or for an even more
asymmetric split. Nevertheless, for a log-normal distri-
bution having such a split (i.e., 91.5 %/8.5 %), the mean
(t) for that portion of a log-normal population, which is
at or above the mean for the entire distribution {i.e.,
P(MS)}, is more than 4-fold less than the minimum
mean for the odds at P(MS|G)– see Additional file 1.
Thus, in this circumstance:
P MSjGð Þ > 4:6t
As such, P(MS|G) cannot be the mean for this portion
of a log-normal distribution (see Additional file 1). This
situation is changed only slightly with even much more
asymmetric splits. Thus, even when the distribution is
severely asymmetric and P(G) is truly tiny (e.g., 10−14),
there is still a more than 3-fold difference between
P(MS|G) and the mean of that portion of the log-normal
distribution, which is at or above P(MS). Indeed, even in
these extreme circumstances:
P MSjGð Þ > 3:1t
Consequently, having a mean for the odds of getting
MS in the (G) population {i.e., P(MS|G)}, which is more
than 12*P(MS), is not compatible, under any circumstance,
with the subset (G) simply being a part of a unimodal log-
normal distribution (Additional file 1: Figure S2B).
It might be argued that such a bimodal structure implies
that evidence of either strong interactions or linkage should
be present – neither of which has been found. However,
with so many genes involved (>150) and such a small
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Fig. 1 Plots of the distribution of MS-probabilities in the (W) set − i.e., from the combined set (GT) − are shown in two hypothetical circumstances,
chosen to match the conditions derived from the Model. Because, as noted in the text, {PMS|G) > 12 * P(MS)}, the minimum asymmetry of the distribution
is far too great to be explained by a log-normal distribution (see Additional file 1). For illustrative purposes only, the distriburtion of the MS-probabilities in
both of the (GT) subsets are plotted as normal. However, because of the large difference in sub-subset means (see text and below), this arbitrary choice
makes no difference to the final conclusions [29]. The means (μ) and standard deviations (σ) for the two distributions have been chosen to fit with the
following four derived or defined relationships (see text and Additional file 1): 1. E(X) = x= P(MS|G)≥ 0.059; 2. 0 < y= P(MS|Gmin) < P(MS)≤ 0.005; 3.
P(MS) = P(G)x+ P(Gmin)y and: 4. σX2 = E(xi− x)2≤ 0.0013 ; ∴ σX≤ 0.036. Thus, for the distribution surrounding P(MS|G), these values have been taken to be
(μ1 = 0.055 ; σ1 = 0.036) and for the distribution surrounding P(MS|Gmin), they have been taken to be (μ2 = 0.0025 ; σ2 = 0.001). The total area underneath
the entire (W) distribution (depicted) is equal to P(GT). The areas underneath each sub-distribution {i.e., splitting the two distributions at P(MS)}, are equal to
P(G) and P(G min), respectively. For the first distribution, (μ1) is slightly less than {x = P(MS|G)} because a small portion of the left-hand tail of this distribution
belongs to the (G min) subset. The first plot (panel A), considers the distribution of (W) in a circumstance where the distribution of MS probabilities in
the combined (GT-) set is unlikely to be bimodal {i.e., where P(G-) = 0}. In this circumstance, the area underneath (and, thus, the height of) the curve
representing the (X) distribution (i.e., for the “genetically susceptible” subset) depends upon the value of P(MS,G min). Thus: 5. when: P(MS,Gmin) ≈ 0; then:
P(G) ≈ P(MS)/x; 6. when: P(MS,Gmin)≈ 0.5 * P(MS); then: P(G)≈ 0.5 * P(MS)/x; 7. when: P(MS,Gmin)≈ P(MS); then: P(G)≈ 0. However, because {P(MS,Gmin)≤
0.56 * P(MS)}, circumstance #7 is impossible (see Additional file 1). Panel A represents circumstance #6. By contrast, the second plot (panel B), considers the
distribution of (W) in a circumstance where the distribution of (Z) is definitely bimodal. Specifically this figure considers the circumstsnce, in which: P(G−) >
0.83; and: P(Gmin)≤ P(G). In the particular case illustrated − i.e., where P(Gmin)≈ P(G) ≈ 0.0425 − the distribution is actually trimodal although the zero
probability of MS for the subset (G-) subset is not depicted in the graph, despite the fact that this subset constitutes the large majority of the population. If
the distribution for the (G min) subset were assumed to have a uniform distribution, on the plot in Panel B, the plateau of the (G min) distribution would be
above the population frequency of (0.0008) and, thus, would still be clearly bimodal. This same pattern persists regradless of the actual value chosen for
P(G) ≈ P(Gmin). Both panels A and B demonstrate the severly bimodal character for the (W) distribution that results under any circumstance. Indeed, such
severe bimodality will exist, regardless of the acutal shape of the distribution of MS probabilities for members of each of the two subsets of (GT). This is both
because of the extreme separation of the subset means and because of the very restricted range for the MS probabilities within the (G min) subset [29]
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fraction of the population being in the subset (G), this is
not the case. Indeed, considering only susceptibility genes,
it seems very likely that almost all MS patients will have a
unique genotype (Additional file 1) and, empirically, this
seems to be true. Thus, using the first 95 MS-associated
SNPs identified in the WTCCC data set [6, 7], 105 of the
genotypes (at these SNP locations) were identical in, at
least, 1 pair of MS cases. Nevertheless, regardless of the
basis for these apparent duplications, for all of the other
10,643 MS cases in this dataset, their genotypes (at these
SNP locations) were unique. Moreover, none of these
apparently duplicated genotypes bore any obvious re-
semblance to each other – sharing identity at only 43
(on average) and 59 (at most) of the 95 SNPs. Under
such circumstances, almost certainly, there will be no
linkage and no strong interactions, even if the popula-
tion (P0) is bimodal.
13. There are two further possibilities. First, it could be
that {P(Gmin) ≤ P(G)}. In this case, the distribution
of MS probabilities within (W) − i.e., for members
of the (GT) subset − could either be symmetric or
not. This relationship necessarily pertains for any
symmetric distribution of (W) because, by definition,
and from the above considerations:
P MSjGTð Þ ¼ P MS;GTð Þ=P GTð Þ
¼ P MSð Þ=P GTð Þ≥P MSð Þ
From this it follows that, any symmetric distribution
for (W) must be centered on some probability value (μ)
such that:
x≥μ ¼ PMSjGT Þ≥PðMSÞ
and, thus, that:
PðGÞ≥PðGminÞ
However, regardless of the nature of the distribution
of (W), if this relationship holds, then it must also be the
case that:
PðG−Þ ¼ 1−PðGÞ−PðGminÞ≥1−2  PðGÞ≥0:83
In addition, the actual values that P(G min) can take
will depend, in part, upon value of P(G).
For example, when P(G) is at its upper-bound of:
P Gð Þ ¼ P MSð Þ=x
then:
PðGminÞ ¼ 0
From this point, as the quantity P(G min) becomes lar-
ger, the quantity P(G) will have to become smaller in
order to maintain the relationship:
PðMSÞ ¼ PðGÞxþ PðGminÞy
Therefore, we conclude that, if P(Gmin) ≤ P(G), then
it must also be the case that the large majority of the
population (P0) must be in the (G-) subset and that the
distribution of (Z) is, at least, bimodal.
14. Second, it could be that: {P(G min) > P(G)}. In this
case, the extreme separation of the subset means
within (W) − i.e., the separation of P(MS|G) from
P(MS|G min) − together with the very restricted
range for the MS probabilities in the (G min) subset,
again indicates that the distribution of {wi} within the
set (W) must be bimodal [30]. This is illustrated in
Fig. 1b, in which the resulting extreme bimodality is
demonstrated even for the circumstance where:
PðGminÞ≈PðGÞ≈0:0425
Again, the means and variances for the distributions
used in this illustration are based on considerations devel-
oped in (9) above. This same pattern (as illustrated) persists
regradless of the value chosen for P(G) ≈ P(Gmin).
Discussion
Using very broad range-estimates for the basic epi-
demiological parameters of MS-prevalence and the re-
currence risk of MS in MZ-twins, this analysis indicates
that no more than 8.5 % of individuals in the general
population can possibly be “genetically susceptible” to
developing MS as herein defined. In all likelihood, this
percentage is actually much smaller [2, 3]. In addition,
as demonstrated in Additional file 1, more than 43 %
(and, likely, more than 84 %) of MS cases develop
through this genetic pathway. Importantly, each of these
estimates are based on directly-observable population
parameters, which have been repeatedly verified in dif-
ferent parts of the world.
The implications of these conclusions are substantial.
Recall that the subset (G min) is defined as consisting of
only those individuals who have very low individual ex-
pected life-time probability values of more than zero but
less than P(MS). By contrast, individuals in the (G) sub-
set, collectively, have an expected life-time probability of
MS at least 12 times the maximum possible either for
that of the (G min) subset as a whole or for that of any
individual member of this subset.
Consequently, even though this analysis does not as-
sume that a group of individuals who are “genetically
susceptible” is distinct from other individuals in the
population, it does, in fact, establish that these two
groups can be so distinguished. Thus, based on the
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PðG−Þ ¼ 1−PðGminÞ−PðGÞ≥1−2  PðGÞ > 0:83
And, in this situation, the two groups are distinguished
by the fact that members of the “non-susceptible” subset
(G-), which represents the overwhelming majority of the
population, are at no risk of developing MS, regardless
of their environmental exposure.
Conversely, if: P(G min) > P(G)
Then, from (14) above, even considering only those in-
dividuals who belong to the combined (GT) subset, the
extreme separation of the means of P(MS) and P(MS|G),
together with the very narrow range of MS probabilities
within the (G min) subset, requires the distribution of in-
dividual expected life-time MS probabilities in the set
(W) to be bimodal [30] and, thus, to reflect the existence
of two distinct groups of MS patients (see Fig. 1a; Add-
itional file 1: Figure S2B). In this circumstance, the two
classes of MS patients are distinguished by the fact that
the MS, which develops, seems to be caused by two, fun-
damentally different, pathophysiological mechanisms. If
the subset (G min) is, indeed, non-empty, then, in the
first mechanism, MS is very improbable, the genetic
contribution seems to be minor, and, thus, environmen-
tal factors are likely to be primary. By contrast, in the
second mechanism, MS is comparatively much more
likely to occur and the combination of both genetic and
environmental events are each critical determinants of
disease. Importantly, if a second group of individuals
with non-zero probabilities of MS actually exists, then,
despite the fact that environmental factors would be in-
volved in both mechanisms, there is no reason to expect
that the environmental events involved in the first path-
way are the same as (or even similar to) those involved
in the second pathway.
In most cases of MS, the genetic route seems to dom-
inate (Additional file 1). Indeed, more than 94 % of con-
cordant MZ-twins {i.e., individuals in the (MS,IGMS)
sub-subset} come from the (G) subset (Additional file 1).
However, these observations do not mean that the genetics
primarily determines the disease, even in these cases. In
fact, the increasing prevalence of MS world-wide [32–40],
its increasing prevalence in women [32, 34, 36, 39, 40], and
the change in prevalence and MZ-twin concordance based
on latitude [3, 12] are better explained by differences in
environmental exposure and by a women’s greater
physiological responsiveness to environmental events
(Additional file 1) than by any differences in genetic
susceptibility between groups or regions [2, 3]. Also,
given the wide disparity between the probability of de-
veloping MS between men and women, the set (G)
must itself be bimodal (Additional file 1).
These conclusions also have important implications
with regard to our ability, ultimately, to determine a per-
son’s risk through genetic analysis. Indeed, if more than
84 % of MS occurs in the genetically susceptible population
(G) and less than 8.5 % of the population is susceptible, it
should be possible, in theory, to characterize a person’s in-
dividual risk with high sensitivity and specificity. The fact
that it has proven difficult to do this so far probably relates,
in part, to the fact that the genetic associations have been
defined on the basis of SNPs [4–7] rather than on the basis
of more extended SNP-haplotypes [41, 42].
Conclusions
It is possible to distinguish two classes of persons in the
general population, indicating either that MS can be
caused by two fundamentally different pathophysiological
mechanisms or that the large majority of the population
is at no risk of the developing this disease regardless of
their environmental experience. Moreover, although
environmental-factors would play a critical role in both
mechanisms (if both exist), there is no reason to expect
that these factors are the same (or even similar) between
the two.
The definitions for the parameters used in the model
are presented in Table 1.
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